These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3978249)

  • 21. Chemo- or endocrine adjuvant therapy alone or combined in postmenopausal patients (GABG Trial 1).
    Jonat W; Kaufmann M; Abel U
    Recent Results Cancer Res; 1989; 115():163-9. PubMed ID: 2696028
    [No Abstract]   [Full Text] [Related]  

  • 22. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hormonotherapy of metastatic breast cancer with tamoxifen and medroxyprogesterone acetate. Randomized trial comparing alternating sequences with successive applications].
    Mauriac L; Durand M; Bonichon F; Chauvergne J
    Bull Cancer; 1986; 73(2):148-54. PubMed ID: 2942203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer.
    Porzsolt F; Otto AM; Trauschel B; Buck C; Wawer AW; Schönenberger H
    J Cancer Res Clin Oncol; 1989; 115(5):465-9. PubMed ID: 2478560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen.
    Vorgias G; Koukouras D; Tzoracoeleftherakis E; Paleogianni V; Androulakis J
    Anticancer Res; 2000; 20(5C):3849-54. PubMed ID: 11268466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys.
    Jerome CP; Power RA; Obasanjo IO; Register TC; Guidry M; Carlson CS; Weaver DS
    Bone; 1997 Apr; 20(4):355-64. PubMed ID: 9108356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
    Johansen JS; Hassager C; Pødenphant J; Riis BJ; Hartwell D; Thomsen K; Christiansen C
    Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
    J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic parameters of nandrolone (19-nortestosterone) after intramuscular administration of nandrolone decanoate (Deca-Durabolin) to healthy volunteers.
    Wijnand HP; Bosch AM; Donker CW
    Acta Endocrinol Suppl (Copenh); 1985; 271():19-30. PubMed ID: 3865478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group.
    Byrne MJ; Gebski V; Forbes J; Tattersall MH; Simes RJ; Coates AS; Dewar J; Lunn M; Flower C; Gill PG; Stewart J
    J Clin Oncol; 1997 Sep; 15(9):3141-8. PubMed ID: 9294477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A randomized, double-blind, placebo-controlled, phase 3 trial comparing SMS 201-995 pa LAR plus tamoxifen versus tamoxifen plus placebo in women with locally recurrent or metastatic breast cancer].
    Sommer H; Pröhl-Steimer B; Bajetta E; Haus U; Janni W; Kay A
    Zentralbl Gynakol; 2001 Oct; 123(10):557-61. PubMed ID: 11753809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer.
    Kakolyris S; Samonis G; Koukourakis M; Vlachonicolis J; Kalbakis K; Agelaki S; Chalkiadakis G; Sanidas E; Tsiftsis D; Georgoulias V
    Am J Clin Oncol; 1999 Jun; 22(3):273-7. PubMed ID: 10362335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of nandrolone decanoate on rarefying bone tissue.
    Dhem A; Ars-Piret N; Waterschoot MP
    Curr Med Res Opin; 1980; 6(9):606-13. PubMed ID: 7408528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virilization of the voice in post-menopausal women due to the anabolic steroid nandrolone decanoate (Decadurabolin). The effects of medication for one year.
    Gerritsma EJ; Brocaar MP; Hakkesteegt MM; Birkenhäger JC
    Clin Otolaryngol Allied Sci; 1994 Feb; 19(1):79-84. PubMed ID: 8174308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection.
    Gold J; High HA; Li Y; Michelmore H; Bodsworth NJ; Finlayson R; Furner VL; Allen BJ; Oliver CJ
    AIDS; 1996 Jun; 10(7):745-52. PubMed ID: 8805865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
    Gennari C; Agnusdei D; Gonnelli S
    Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
    Bonneterre J; Buzdar A; Nabholtz JM; Robertson JF; Thürlimann B; von Euler M; Sahmoud T; Webster A; Steinberg M; ;
    Cancer; 2001 Nov; 92(9):2247-58. PubMed ID: 11745278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
    Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
    J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.